Newsroom

Chicago, IL, October 3, 2005: Angiogen announced today that Dr. Gerald Soff, its Founder and Chief Scientific Officer, is the lead author of an article published in the September 1, 2005 issue of Clinical Cancer Research (Vol. 11, 6218-6225).

Sept. 1, 2005: Clinical Cancer Research, a respected oncology journal, publishes article by Dr. Gerald Soff, et al, about angiogenesis inhibition. The article discusses the findings of Angiogen's early Phase I clinical trial with Genentech. Click to read an abstract with link to full-text download.

• "This study shows that in vivo generation of AS4.5 is safe in humans and may provide a practical approach to achieve antiangiogenic therapy."

May 17, 2005: Introducing Angiogen: Article and audio interview with Mark Arizmendi, president of Angiogen, LLC. [Wall Street Reporter]

May 16, 2005: Arizmendi to present at Midwest Venture Summit on 5/20/05

May 9, 2005: Angiogen is one of three companies in a unique incubator program being aided by the Center for Women Entrepreneurs in Technology. [Chicago Sun-Times]

 

Contact us to learn more about Angiogen, LLC and the new cancer therapies the company is developing.